Trevi Therapeutics price target raised to $12.50 from $7.50 at H.C. Wainwright

H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Trevi Therapeutics (TRVI) to $12.50 from $7.50 and keeps a Buy rating on the shares after the company announced topline results for the RIVER Phase 2a study of Haduvio in refractory chronic cough that the firm calls a “homerun.” The “remarkable” cough reductions consistent with the prior idiopathic pulmonary fibrosis chronic cough CANAL Phase 2a trial should increase investor confidence in the odds of success of both the IPF-CC and RCC clinical programs and FDA approval, the analyst tells investors.